Special Issue

New Perspectives on the Measurement of Free Light Chains in the Different Matrices: Serum, Urine, and Cerebrospinal Fluid

Message from the Guest Editor

The determination of free light-chains (S-FLCs) in serum has been a turning point in the diagnosis, prognosis, and monitoring of monoclonal gammopathies of undetermined significance (MGUS), multiple myeloma (MM), and light-chain amyloidosis (AL). The method, established in the 2000s, quantifies serum-FLC using polyclonal antibodies to identify the presence and pattern of multiple myelomas in patients; meanwhile, the assays are nowadays more often based on monoclonal antibodies. Since the FLC are the isoforms, kappa (□) and lambda (□), of the light chains of immunoglobulins that circulate unbound in the serum, in order to facilitate the interpretation, the results of their quantities will be accompanied by a ratio. The calculated value of □/□ free chains (FLC) relative to the reference intervals may indicate the presence of plasma cell dyscrasias in the patient, such as multiple myeloma or AL amyloidosis. The Special Issue will also address the possible benefits of using the new generation FLC tests and new experimental approaches used in laboratories.

Guest Editor

Dr. Massimo Pieri
Department of Experimental Medicine, University of Tor Vergata, 00133 Rome, Italy

Deadline for manuscript submissions

closed (30 April 2024)

Diseases

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/si/179781

Diseases
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diseases@mdpi.com

mdpi.com/journal/diseases

Diseases

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/journal/diseases

About the Journal

Message from the Editorial Board

Diseases is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets. *Diseases* is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Maurizio Battino
Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biochimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

Prof. Dr. Omar Cauli
Frailty and Cognitive Impairment—FROG Research Group, University of Valencia, 46010 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

MDPI